New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For AET;RHHBY;MCD;DST;SYT;AKR;ATHN;TSM;MPEL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
March 20, 2015
11:33 EDTRHHBYFly Review: Analysts correctly predict jump in Biogen shares
The shares of Biogen (BIIB) are rallying after the company reported results for a Phase 1b study of its Alzheimer's drug, BIIB-037. On March 18, as reported on that day by The Fly, RBC Capital predicted that the stock would rise after the results were published. A number of other firms were also upbeat on the stock ahead of the data release. WHAT'S NEW: Earlier this morning Biogen announced that the three milligram, six milligram, and ten milligram dose versions of its Alzheimer's treatment, aducanumab, had reduced the amount of amyloid plaque in the brains of Alzheimer's patients taking the drug by statistically significant amounts compared with those taking placebos. Beta amyloid is a protein that produces plaque in the brain. Scientists suspect that plaques in the brain are a cause of Alzheimer's. The cognitive decline of patients taking BIIB-037 was also significantly less than that of patients who were taking placebos, the company reported. PRE-EVENT CALLS: RBC Capital analyst Michael Yee predicted earlier this week in a note to investors that Biogen would report strong data for BIIB-037 and the stock should "work higher" after the data is unveiled. Alzheimer's patients taking the high dose of Biogen's BIIB-037 drug should exhibit a stabilization of cognition levels, Yee stated. Conversely, the cognition levels of patients taking the placebo should drop slightly, the analyst predicted. On March 13, in a note summarized by The Fly on that day, JPMorgan recommended buying Biogen shares ahead of the data release. Investors still incorporated a low probability of success for the drug, and the stock could rise further, the firm wrote. On March 19, in a note also published by The Fly, Credit Suisse wrote that Biogen's multiple could rise if the data on BIIB-037 was positive. It raised its price target on the name to $500 from $400. ANALYST REACTION: This morning, Barclays raised Biogen's price target to $500 from $435 following the company's report of "impressive" full results from the Alzheimer's study. Piper Jaffray analyst Joshua Schimmer also raised his price target for Biogen shares to $500 this morning, calling today’s BIIB-037 results "robust and impressive." Schimmer believes the trial showed a "consistent and dramatic" dose effect on both radiographic and clinical disease features and thinks the side effects "pale in comparison" to the drug’s efficacy. OTHERS TO WATCH: Eli Lilly (LLY) and Roche (RHHBY) are also currently developing similar Alzheimer's treatments. PRICE ACTION: In late morning trading, Biogen rose 7% to $464. The stock is up about 9% since Wednesday. Eli Lilly shares are up 1.6% to $75.40 this morning, while Roche rose 2.2% to $35. Reference Link
09:01 EDTRHHBYEli Lilly up 2% to $75.75 in pre-market trading
Subscribe for More Information
08:18 EDTAETLeerink healthcare services analyst holds an analyst/industry conference call
Healthcare Services Analyst Gupte discusses Sustainable Growth Rate (SGR) and the proposed pay-fors and implications For Healthcare Services on an Analyst/Industry conference call to be held on March 20 at 11 am.
05:58 EDTTSMTaiwan chipmakers unaffected by water shortages, DigiTimes reports
Subscribe for More Information
March 19, 2015
16:14 EDTRHHBYProthena report positive results from Phase 1 study of PRX002
Subscribe for More Information
13:00 EDTMPELCasino operators jump after analyst starts with Buy ratings
Subscribe for More Information
10:02 EDTMPELOn The Fly: Analyst Initiation Summary
Subscribe for More Information
10:02 EDTAETOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:20 EDTAETAetna upgraded at Sterne Agee
As noted earlier, Sterne Agee upgraded Aetna to Buy from Neutral. The firm says that the company is the best-positioned name within the large-cap health plan space , a defensive sector that has little exposure to Europe and reasonable growth prospects, according to the firm.
07:02 EDTRHHBYSigma-Aldrich signs exclusive distribution agreement with Roche
Subscribe for More Information
06:19 EDTAETAetna upgraded to Buy from Neutral at Sterne Agee
Subscribe for More Information
06:15 EDTATHNathenahealth coverage transferred with an Outperform at RW Baird
Subscribe for More Information
March 18, 2015
16:23 EDTMPELMelco Crown initiated with a Buy at Brean Capital
Subscribe for More Information
12:48 EDTRHHBYFly Watch: Biogen predicted to report strong Alzheimer's data this Friday
Subscribe for More Information
12:46 EDTAETAetna, HackensackAlliance ACO announce collaboration
Subscribe for More Information
07:46 EDTRHHBYLilly Roche would have upbeat read through from strong BIIB data, says Bernstein
Bernstein notes that the data for Biogen's (BIIB) Alzheimer's treatment, due to be released on Friday, is widely expected to be positive. The firm thinks that positive data would boost the outlook for similar Alzheimer's drugs being developed by Eli Lilly (LLY) and Roche (RHHBY), since consensus estimates for those drugs are low. The firm keeps Outperform ratings on Eli Lilly and Roche.
March 17, 2015
09:00 EDTAETAetna management to meet with JPMorgan
Subscribe for More Information
08:13 EDTRHHBYCelldex announces clinical trial collaboration with Roche
Celldex Therapeutics (CLDX) announced that it has entered into a clinical trial collaboration with Roche (RHHBY) to evaluate the safety, tolerability and preliminary efficacy of varlilumab, Celldex's CD27 targeting investigational antibody, and MPDL3280A, Roche's investigational cancer immunotherapy in a Phase 1/2 study in renal cell carcinoma. Varlilumab and MPDL3280A are part of a new class of investigational medicines known as cancer immunotherapies that are designed to harness the body's own immune system to fight cancer through separate yet complementary mechanisms of action that may enable the activation of T cells, restoring their ability to effectively detect and attack tumor cells. Preclinical data suggest the combination of these two mechanisms are synergistic and may enhance anti-tumor immune response compared to either agent alone. In Celldex's Phase 1 study of varlilumab in multiple solid tumors, promising signs of clinical activity in patients with refractory renal cell carcinoma were observed, including a durable partial response that has continued to decrease in tumor volume over time and prolonged stable disease. Under the terms of this agreement, Roche will provide study drug and Celldex will be responsible for conducting and funding the study, which is expected to begin in 2015.
06:46 EDTMCDMcDonald's burn complaints to focus on corporate reponsibility, WSJ says
Subscribe for More Information
06:06 EDTMCDMcDonald's employees file complaints of burns, injuries, LA Times says
McDonald's employees have filed complaints against 28 McDonald's locations -- including nine owned by the corporation itself -- alleging they received burns on the job, reports the LA Times, citing statements by union-backed group Fast Food Forward. The complaints were lodged with the Occupational Safety and Health Administration and claim that greasy floors, lack of staff, and an extremely fast-paced environment elevate the risk of injury in McDonald's restaurants. Reference Link
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use